ModernaTX, Inc.
Quick facts
Marketed products
- Fluarix Quadrivalent
- Fluzone HD
- Influenza Vaccine 2
- mRNA-1273.712
- mRNA-1273 Variant-containing Formulation · Immunology / Infectious Disease
mRNA-1273 Variant-containing Formulation encodes instructions for cells to produce spike proteins from SARS-CoV-2 variants, triggering an immune response against those variants. - mRNA-1283 · Oncology
mRNA-1283 is a self-amplifying mRNA vaccine that encodes human papillomavirus (HPV) antigens to stimulate immune responses against HPV-infected cells.
Phase 3 pipeline
- Afluria® Quadrivalent · Immunology / Infectious Disease
Afluria Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. - Alpharix® Tetra · Immunology / Infectious Disease or Oncology
Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously. - Influsplit® Tetra · Immunology / Infectious Disease
Influsplit® Tetra is a quadrivalent mRNA vaccine that encodes influenza virus surface antigens to stimulate immune responses against four strains of influenza. - Investigational mRNA-1273.815 · Immunology / Infectious Disease
mRNA-1273.815 is an mRNA vaccine encoding modified spike proteins designed to elicit immune responses against SARS-CoV-2 variants. - Licensed Spikevax Vaccine · Immunology / Infectious Disease
Spikevax is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to protect against COVID-19 infection. - mRNA-1010 · Oncology
mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells. - mRNA-1083 · Musculoskeletal
mRNA-1083 encodes an optimized full-length human myostatin propeptide to inhibit myostatin activity and promote muscle growth. - mRNA-1273.815
- mRNA-1283.222 · Infectious Diseases
mRNA-1283.222 is a messenger RNA-based vaccine that encodes for a specific protein to stimulate an immune response. - mRNA-1283.815 · Infectious disease
mRNA-1283.815 is a messenger RNA-based vaccine that encodes for a specific protein to stimulate an immune response. - mRNA-1345 · Infectious Disease
mRNA-1345 is an mRNA-based vaccine designed to prevent COVID-19 infection by inducing an immune response against the SARS-CoV-2 virus. - mRNA-1403 · Infectious Disease
mRNA-1403 is an mRNA-based vaccine designed to encode for the SARS-CoV-2 spike protein. - mRNA-1647
Phase 2 pipeline
- Adjuvanted Quadrivalent Influenza Vaccine · Immunology
This vaccine induces an immune response against multiple strains of influenza. - Biological: mRNA-1273 · Infectious Disease
mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein - Egg-based Quadrivalent Influenza Vaccine
- Investigational COVID-19 Vaccine Lot A
- Investigational COVID-19 Vaccine Lot B
- Moderna mRNA1273.222 Booster
- mRNA-1010.4
- mRNA-1010.6
- mRNA-1045
- mRNA-1083 Composition 1 Dose A Lot A
- mRNA-1083 Composition 1 Dose A Lot B
- mRNA-1083 Composition 1 Dose B
- mRNA-1083 Composition 1 Dose C
- mRNA-1083 Composition 2 Dose A
- mRNA-1083 Composition 2 Dose B
- mRNA-1083 Composition 3 Dose A
- mRNA-1083 Composition 3 Dose B
- mRNA-1195
- mRNA-1273.213
- mRNA-1273.231
- mRNA-1273.529
- mRNA-1283.211
- mRNA-1283.529
- mRNA-1893
- mRNA-4157
- SPIKEVAX Bivalent
- SPIKEVAX X
Phase 1 pipeline
- COVID-19 Vaccine 1
- COVID-19 Vaccine 2
- Influenza Vaccine 1
- Investigational COVID-19 Vaccine 1
- Investigational COVID-19 Vaccine 2
- Investigational Influenza Vaccine 1
- Investigational Influenza Vaccine 2
- mRNA-1010.2
- mRNA-1010.3
- mRNA-1011.1
- mRNA-1011.2
- mRNA-1012.1
- mRNA-1018 for H5 Only
- mRNA-1018 for H5 Only-CG
- mRNA-1018 for H5N8
- mRNA-1018 for H7 Only
- mRNA-1018 for H7N9
- mRNA-1020
- mRNA-1030
- mRNA-1073
- mRNA-1083.1
- mRNA-1083.2
- mRNA-1083.3
- mRNA-1189
- mRNA-1195.1
- mRNA-1195.2
- mRNA-1230
- mRNA-1325
- mRNA-1365
- mRNA-1405
- mRNA-1443
- mRNA-1468
- mRNA-1608
- mRNA-1653
- mRNA-1769
- mRNA-1944
- mRNA-1975
- mRNA-1982
- mRNA-2752
- mRNA-2808
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about ModernaTX, Inc.
What are ModernaTX, Inc.'s marketed drugs?
Top marketed products include Fluarix Quadrivalent, Fluzone HD, Influenza Vaccine 2, mRNA-1273.712, mRNA-1273 Variant-containing Formulation, mRNA-1283.
What is ModernaTX, Inc.'s pipeline?
ModernaTX, Inc. has 13 drugs in Phase 3, 27 in Phase 2, 50 in Phase 1. Late-stage candidates include Afluria® Quadrivalent, Alpharix® Tetra, Influsplit® Tetra, Investigational mRNA-1273.815.
Related
- Fluarix Quadrivalent
- Fluzone HD
- Influenza Vaccine 2
- mRNA-1273.712
- mRNA-1273 Variant-containing Formulation · Immunology / Infectious Disease
- Sector hub: All tracked pharma companies